Clinical Trial Update: Roflumilast in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Fixed Combinations of Long-acting β2-agonists (LABA) and Inhaled Glucocorticosteroid (ICS) [Phase 4]

View source ↗

Summary

Phase 4 trial assessing roflumilast in COPD patients already receiving fixed LABA/ICS therapy; results were posted in 2015.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Roflumilast (roflumilast)

Snippet

Sponsor: AstraZeneca | Conditions: Chronic Obstructive Pulmonary Disease | Phase 4 | Status: COMPLETED | Results posted: 2015-10-29